MG News Briefs

intravenous medication

Rituximab Trial Shows Decreased Symptoms and Need for Rescue Therapy in MG

Rituximab may be effective in preventing debilitating symptoms of myasthenia gravis (MG), indicating its efficacy as a potential first-line treatment, according to a randomized trial. The results showed that patients who received rituximab had fewer symptoms and needed less rescue therapy at week 16 compared to those in the placebo group. About 70% of patients…

myasthenia gravis overview

Metformin May Regulate Autoimmune Activity in MG

Metformin may reverse some of the autoimmune landmarks in patients with myasthenia gravis (MG), according to an experimental study. In the rodent study, the spleen showed the highest levels of miR-146a, a microRNA previously linked with autoimmune disorders. On the other hand, lymph nodes and the thymus had decreased levels of the same molecule. Moreover,…

infusion bottle

Single Low-Dose Rituximab Infusion May Improve Refractory MG Symptoms

The use of a single low-dose rituximab infusion may help improve symptoms in patients with refractory myasthenia gravis (MG), according to a study published in the Journal of Neurological Sciences. In the small study cohort, 13 out of the 17 patients responded to the rituximab treatment, with 6 even achieving asymptomatic status. The patients who…

Myasthenia gravis etiology

Tacrolimus Improves Symptoms and Modulates Costimulatory Molecules in Refractory MG

Treatment with tacrolimus improves clinical symptoms and modulates plasma levels of soluble costimulatory molecules and their ligands in patients with refractory myasthenia gravis (MG), a recent study suggests. Significant reductions in clinical scores, including the Quantitative MG score (QMG), the MG-specific manual muscle test (MMT), the MG-related activities of the daily living score (MG-ADL), and…

anemia

Anemia Is Common and Reduces Quality of Life in Female Patients With MG

A new study has determined that moderate or severe anemia is relatively common among female patients with myasthenia gravis (MG). The study, published in PLOS ONE, noted that the long-term immunosuppressive treatment commonly administered to patients with MG is a probable cause of anemia. “The causes of anemia are complex and diverse, and some of…

ICU

Several Factors Influence Outcomes for Patients With Myasthenia Gravis in the ICU

Specific factors regarding care in the neurology intensive care unit (ICU) for patients with myasthenia gravis (MG) could predict future complications, according to a study recently published in Neurological Sciences. This retrospective study included 118 patients previously diagnosed with MG who together experienced 130 severe exacerbations that required admission to the neurology ICU at a…

surgery

Surgeons Face Steep Learning Curve for Robot-Assisted Thymectomy

A new single-center retrospective study has reported that the learning curve for a single surgeon to learn robot-assisted thymectomy (RAT) for patients with myasthenia gravis (MG) is steep, requiring 16 procedures to achieve the completion of the learning curve for the surgical time. The study, published in Frontiers in Surgery, reported that even more procedures…

vaccine

MG Patients Treated With Efgartigimod Still Generate Immune Response When Vaccinated

Efgartigimod does not impair the ability of patients with myasthenia gravis (MG) to generate new specific immunoglobin G (IgG) responses, regardless of the timing of vaccinations, a new study published in Autoimmunity found. These findings suggest that efgartigimod treatment has no effect on long-lived plasma cells and that protective antibody levels obtained via vaccination can…

viral infection bacteria

Thymoma-Associated MG With Immunodeficiency Increases Infection Risk

A new study reports that patients with thymoma-associated myasthenia gravis (MG) who also have immunodeficiency are at an elevated risk of infection and require additional vigilance during follow-up. The study, published in the Journal of Neuroimmunology, notes that efgartigimod, a new treatment for MG, can lead to hypogammaglobulinemia, which underscores this risk. “Efgartigimod can decrease…

Blood test

TRAF6: A Potential Biomarker of Inflammation and Treatment Efficacy in MG

Tumor necrosis factor receptor-associated factor 6 (TRAF6) may be a potentially useful biomarker of inflammation and treatment effectiveness in patients with myasthenia gravis (MG), according to a study published in BMC Neurology. Expression levels of TRAF6 were found to be elevated in CD19+ B cells and CD19+CD27+ memory B cells in patients with MG during…

Next post in MG News Briefs